Outlook Therapeutics raises ~$5M in registered direct offering at $0.5855/share; warrants repriced

Outlook Therapeutics, Inc.

Gross proceeds of ~$5.0M from sale of 8,539,709 shares at $0.5855 per share.
Warrant amendment reduces exercise price of 15,488,570 warrants from $1.78 to $0.5855.
Offering expected to close May 29, 2026; net proceeds for working capital and general corporate purposes.
Purchaser GMS Ventures is affiliated with directors Yezan Haddadin and Faisal G. Sukhtian.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.